Parsabiv
Biological
Amgen Inc.
Total Payments
$7.0M
Transactions
44,827
Doctors
6,822
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $176,929 | 251 | 182 |
| 2023 | $241,950 | 1,553 | 936 |
| 2022 | $348,393 | 5,475 | 2,351 |
| 2021 | $545,106 | 6,765 | 2,644 |
| 2020 | $476,268 | 3,436 | 1,721 |
| 2019 | $1.9M | 9,625 | 2,976 |
| 2018 | $1.7M | 10,796 | 3,381 |
| 2017 | $1.6M | 6,926 | 2,766 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.1M | 1,818 | 43.6% |
| Unspecified | $1.7M | 407 | 24.8% |
| Food and Beverage | $1.1M | 40,199 | 15.2% |
| Travel and Lodging | $616,801 | 2,201 | 8.8% |
| Consulting Fee | $484,059 | 152 | 6.9% |
| Space rental or facility fees (teaching hospital only) | $51,100 | 28 | 0.7% |
| Education | $201.40 | 22 | 0.0% |
Payments by Type
General
$5.3M
44,420 transactions
Research
$1.7M
407 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Pediatric Multi-Dose | Amgen Inc. | $698,337 | 1 |
| The effect of etelcalcetide on bone-tissue properties and calcification propensity in end stage kidney disease | Amgen Inc. | $532,000 | 0 |
| OLE 2 | Amgen Inc. | $240,790 | 4 |
| AMG 416 Pediatric | Amgen Inc. | $135,620 | 0 |
| Ph3 KAI 4169 Secondary HPT 2 | Amgen Inc. | $47,005 | 3 |
| Ph3 Head to Head: Comparison of Cinacalcet vs. AMG 416 in Cinacalcet Naive Subjects | Amgen Inc. | $26,146 | 4 |
| PH3 KAI 4169 Secondary HPT OLE | Amgen Inc. | $18,942 | 3 |
| Etelcalcetide-induced changes in serum calcium and bone turnover markers and the severity of second | Amgen Inc. | $18,578 | 3 |
| Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm | Amgen Inc. | $11,263 | 1 |
| Exploration of the Symptom and Health-Related Quality of Life Burden of Secondary Hyperparathyroidism in Chronic Kidney Disease Patients on Dialysis | Amgen Inc. | $5,929 | 0 |
| Ph3 KAI 4169 Secondary HPT 1 | Amgen Inc. | $4,219 | 5 |
| Economic consequences to CMS of including calcimimetics in the End-Stage Renal Disease (ESRD) payment bundle | Amgen Inc. | $2,500 | 1 |
| Incidence of comorbidities in Psoriatic Arthritis | Amgen Inc. | $1,676 | 1 |
| Validation of the Nausea and Vomiting Symptom Assessment Patient Reported Outcome Instrument among Chronic Kidney Disease Patients on Dialysis with Secondary Hyperparathyroidism | Amgen Inc. | $790.02 | 0 |
| Ph3 SWITCH Study: Converting from Cinacalcet to AMG 416 | Amgen Inc. | $71.12 | 2 |
Top Doctors Receiving Payments for Parsabiv
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $1.8M | 416 |
| , M.D | Nephrology | Huntsville, AL | $301,252 | 403 |
| , MD | Nephrology | Los Angeles, CA | $286,626 | 327 |
| , M.D | Internal Medicine | Webster, TX | $249,977 | 327 |
| , M.D | Internal Medicine | Rancho Mirage, CA | $232,452 | 274 |
| , M.D | Nephrology | Alexandria, VA | $207,682 | 328 |
| , MD | Nephrology | Saint Louis, MO | $188,501 | 313 |
| , MD | Nephrology | St Louis, MO | $188,194 | 230 |
| , MD | Nephrology | Bronx, NY | $170,549 | 276 |
| , MD | Nephrology | Greensboro, NC | $128,907 | 209 |
| , M.D | Nephrology | Greenville, NC | $126,616 | 181 |
| , MD, PHD | Internal Medicine | Meridian, ID | $113,102 | 159 |
| , M.D | Nephrology | Kerrville, TX | $110,700 | 153 |
| , MD | Internal Medicine | Pittsburgh, PA | $97,952 | 160 |
| , MD | Nephrology | Beachwood, OH | $87,950 | 119 |
| , MD | Nephrology | Birmingham, AL | $86,983 | 107 |
| , DO | Nephrology | Evanston, IL | $85,509 | 115 |
| William Goodman | — | Los Angeles, CA | $84,897 | 90 |
| , MD | Nephrology | Augusta, GA | $70,473 | 85 |
| , DO | Internal Medicine | Pittsfield, MA | $68,265 | 66 |
| , M.D | Nephrology | San Antonio, TX | $66,630 | 85 |
| , DO | Nephrology | Allentown, PA | $61,737 | 80 |
| , A.R.N.P | Nurse Practitioner | Winter Park, FL | $60,483 | 163 |
| , M.D | Nephrology | Santa Paula, CA | $56,931 | 77 |
| , D.O | Nephrology | Newark, DE | $54,166 | 84 |
Ad
Manufacturing Companies
- Amgen Inc. $7.0M
Product Information
- Type Biological
- Total Payments $7.0M
- Total Doctors 6,822
- Transactions 44,827
About Parsabiv
Parsabiv is a biological associated with $7.0M in payments to 6,822 healthcare providers, recorded across 44,827 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $176,929 was paid across 251 transactions to 182 doctors.
The most common payment nature for Parsabiv is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.1M, 43.6% of total).
Parsabiv is associated with 15 research studies, including "Pediatric Multi-Dose" ($698,337).